Diabetes and ischemic heart disease: double jeopardy with regard to depressive mood and reduced quality of life

Natasha Bergmann1,†, Søren Ballegaard2, Pernille Holmager1, Per Bech3, Åke Hjalmarson4, Finn Gyntelberg5 and Jens Faber1,6

1Department of Endocrinology, Herlev University Hospital, Herlev, Denmark
2Ull Care A/S, Hellerup, Denmark
3Psychiatric Research Unit, Psychiatric Center North Zealand, Hillerød, Denmark
4The Cardiovascular Institute, Sahlgrenska University Hospital, Goteborg, Sweden
5The National Research Center for the Working Environment, Copenhagen, Denmark
6Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark

†N Bergmann is now at Endocrine Unit, Department of Medicine, Herlev University Hospital, 2730 Herlev, Denmark

Correspondence should be addressed to N Bergmann
Email n.c.bergmann@hotmail.com

Abstract

The aim of this study was to test i) whether patients having diabetes and ischemic heart disease (IHD), i.e., patients suffering from two chronic diseases, demonstrate a higher degree of chronic stress when compared with patients suffering from IHD alone, and ii) whether suffering from the two chronic diseases results in an elevation in specific elements of the chronic stress concept. A total of 361 participants with IHD were included, of whom 47 suffered from concomitant diabetes. Stress was measured by pressure pain sensitivity (PPS) and by the following questionnaires: the Major Depression Inventory (MDI), the SF-36 Quality of Life questionnaire (SF-36 QOL), the WHO-5 Well-being Index, and the clinical stress signs (CSSs) scale. Participants with diabetes and IHD had a higher MDI score, a lower SF-36 physical component summary score, and a lower score of several sub-measurements of the SF-36 mental component score when compared with patients with IHD without diabetes. No significant differences were observed regarding stress measured by the PPS measure, the WHO-5 Well-being Index, or the number of CSSs. In conclusion, the combination of diabetes and IHD seems to be associated with increased depressive symptoms, lower overall physical QOL, and reduced mental QOL on several sub-elements of the questionnaire. This should be recognized in the management of patients with double diagnoses.

Key Words
- diabetes
- ischemic heart disease
- psychological stress
- depressive symptoms
- well-being
- pressure pain sensitivity

Introduction

The risk of depression in people with diabetes is two times higher when compared with patients without diabetes, and major depression and elevated depressive symptoms have been found to be present in 11 and 31%, respectively, of individuals suffering from diabetes (1). The 12-month odds ratio of major depression is also increased more than twice in outpatients after a myocardial infarction (MI) (2) and ~20% of outpatients...
with stable coronary artery disease have depressive symptoms (Patient Health Questionnaire ≥ 10) (3). Similarly, psychosocial stress is increased both in patients with diabetes and in patients with ischemic heart disease (IHD), and stress is generally accepted to be a risk factor for a poor outcome in both patient groups (4, 5, 6). The combination of suffering from both diabetes and IHD is very common as the presence of diabetes doubles the age-adjusted risk for cardiovascular disease in men and triples it in women (7). However, the psychological impact of suffering from both chronic diseases simultaneously still needs to be evaluated.

A newly developed handheld device measuring stress-induced hyperalgesia as pressure pain sensitivity (PPS) has shown promising results as a new measure of chronic stress both alone and in combination with a score of clinical stress signs (CSSs) (8, 9). A high PPS has previously been found to correlate with well-known stress reactions such as blood pressure, pulse rate, and work of the heart in healthy individuals (9), and to correlate with elements of stress as depressive symptoms, reduced well-being, and reduced quality of life (QOL) in patients with IHD (8). Thus, PPS may be used as a semi-objective measure covering the whole concept of stress.

In this study, we questioned i) whether patients having both diabetes and IHD, i.e., patients suffering from two chronic diseases, demonstrate a higher degree of chronic stress when compared with patients suffering from IHD alone, as measured by PPS and validated questionnaires evaluating depressive symptoms, QOL, psychological well-being, and CSSs, and ii) whether suffering from the two chronic diseases results in an elevation in specific elements of the chronic stress concept when compared with patients suffering solely from IHD.

**Materials and methods**

The materials and methods followed in this study have been described in detail previously (8). In short, this was a cross-sectional study of patients with established and stable IHD. The inclusion criteria were as follows: established IHD defined as having a previous MI, or percutaneous coronary intervention, or coronary artery bypass graft surgery) and having completed cardiac rehabilitation more than 6 months before inclusion. The exclusion criteria were as follows: age over 75 years; suffering from unstable IHD such as scheduled cardiac surgery or changes in heart medication within 1 month before inclusion; hospitalization due to psychiatric disease; and suffering from other chronic competing disorders, which clearly impaired the participant’s QOL.

PPS was measured by an algometric device, which quantifies the induced sensitivity for pressure experienced when stressed. The measurement was performed by a professional instructor after ten minutes of rest in a supine position on the most sensitive point on the sternum in the area of IC 4–5 and has been described in detail previously (8, 9, 10).

The following questionnaires were used for evaluating the different elements of the chronic stress concept: the Major Depression Inventory (MDI), which measures depressive symptoms, with a higher score equaling more depressive symptoms; the SF-36 Quality of Life questionnaire (SF-36 QOL), measuring physical and psychological QOL with a higher score equaling a better QOL; the WHO-5 Well-being Scale (WHO-5), with a higher score measuring a higher psychological well-being; and a newly developed questionnaire, the Clinical Stress Scale questionnaire, CSS, which includes a score of 56 CSSs experienced during the last 4 weeks, with each stress sign equaling one point on the scale (8). The questionnaires were answered on a website established for the study (www.songheart.org), and each participant had a personal login, which was first opened after the study ended in order to avoid bias.

As this study aimed to evaluate the influence on stress caused by the knowledge of suffering from two chronic diseases, diabetes was diagnosed based on a self-reported history, i.e., the knowledge of having diabetes and not on biochemical cut-off levels.

Participants were recruited from a database on subjects with established IHD (HjerteRask) at the Departments of Cardiology at Gentofte and Herlev University Hospitals, Copenhagen, Denmark. Participants had been rehabilitated according to the national guidelines during the period of 1999–2011 and were recruited to this study between June 2011 and February 2012. Written informed consent was obtained from all participants and the study was approved by the local ethical committee and was registered on www.clinicaltrials.gov (NCT01513824).

**Results**

A total of 361 participants with IHD were included, of whom 47 (13%) suffered from known and concomitant diabetes. Participants with both diabetes and IHD were comparable to participants with only IHD with respect to age, sex, and cardiovascular medication except for use of...
In the present cohort, 58% had a PPS \(\geq 60\), which is regarded as a cut-off value for increased chronic stress (8). This figure was not different in relation to having both diabetes and IHD vs having only IHD. However, in an otherwise healthy population, only 27% have been found to have PPS \(\geq 60\), demonstrating that the present cohort in fact did show signs of elevated stress, i.e., PPS (9). PPS measures pain threshold, and reduced pain threshold (i.e., increased PPS) is observed in several chronic diseases with a secondary generalized pain sensation such as fibromyalgia, arthritis, and post-traumatic stress syndrome (12, 13). Among the sub-items of the physical SF-36 questionnaire was a question of body pain. This parameter was not changed due to the presence of diabetes, and it might be speculated if the reduced score of overall physical QOL is related not to pain in particular, but rather to reduced ability of motion in general, as general stiffness of connective tissue is a well-known entity of long-standing diabetes (14).

In a recent randomized study with 217 participants with IHD receiving either treatment as usual or a program with daily self-measurement of PPS followed by reflection and action if a high PPS was measured, we found that, after 3 months, the active group, measuring PPS, showed a significant decrease in both PPS and MDI, suggestive of lower stress and lower level of depressive symptoms, and reduced mental QOL on several sub-elements.

### Table 2 Psychological status in patients with diabetes and ischemic heart disease (IHD) vs IHD alone. Data are expressed as mean (s.o.).

<table>
<thead>
<tr>
<th></th>
<th>MDI</th>
<th>Major Depression Inventory</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IHD with diabetes (n = 47)</td>
<td>11 (7.7)</td>
<td>0.019</td>
</tr>
<tr>
<td></td>
<td>IHD without diabetes (n = 314)</td>
<td>8.0 (7.0)</td>
<td></td>
</tr>
<tr>
<td>Age, mean (s.o.)</td>
<td>64 (6.1)</td>
<td>62 (19)</td>
<td>0.070</td>
</tr>
<tr>
<td>Calcium antagonists, n (%)</td>
<td>40 (85)</td>
<td>45 (10)</td>
<td>0.001</td>
</tr>
<tr>
<td>Calcium antagonists, n (%)</td>
<td>40 (85)</td>
<td>45 (10)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

*Bold text means \(P < 0.005\).
an increase in WHO-5 as a measure of a higher psychological well-being score, when compared with the group receiving treatment as usual (10). Overall, the Cohen’s effect size was 0.12 between the active and the control groups; however, the effect of the intervention was consistently more pronounced among the psychologically vulnerable subjects with a Cohen’s effect size of 0.35 among the subjects with MDI ≥15 (an effect size similar to the effect of anti-depressive medication) and an effect size of 0.52 among subjects with both high PPS and CSSs (10).

A limitation to this study was the much smaller number of participants in the group with diabetes and IHD (n = 47) when compared with the group with IHD alone (n = 314), which should be acknowledged when interpreting the data. However, the groups were large enough to substantiate a trend toward a more vulnerable psychological profile among patients suffering from both diabetes and IHD. Distinction between patients with diabetes treated with only OHAs and with insulin was hampered by the small numbers, and the lack of differences between these groups should be taken with reservation.

Our findings should be acknowledged when dealing with patients with both diabetes and IHD, i.e., both from a diabetologist’s and a cardiologist’s perspectives. Based on our own study with stress intervention in patients with IHD mentioned above, stress-reducing therapies should be considered at least in patients with both diabetes and IHD. This finding might be broadened out to other clinical situations with combinations of chronic diseases, i.e., psychologically vulnerable patients, in which it is known that QOL is substantially reduced. This clearly calls for further studies.

In conclusion, this study finds that the combination of known diabetes and chronic and stable IHD seems to be associated with increased depressive symptoms, lower overall physical QOL, reduced mental QOL on several sub-elements, but not with reduced pain threshold as measured by PPS. We encourage clinicians to recognize the double jeopardy with regard to psychological and especially depressive symptoms when treating patients with double diagnoses of chronic nature.

Declaration of interest
S Ballegaard invented the instrument used to measure PPS and is a shareholder of the firm that owns the PPS instrument (Ullcare A/S). In order to avoid bias, he was not involved in patient contact, collection of data, or statistical analysis. However, as he was involved in the study design and writing of the protocol and critically reviewed the manuscript, he is entitled to his author privilege. The other authors have nothing to declare.

Funding
This work was supported by the Johan Schrøder’s Family and Business Foundation. N Bergmann has received grants from the Lundbeck Foundation, the Carpenter Sophus Jacobsen and Wife Astrid Jacobsen’s Foundation, and the Else and Mogens Wedell-Wedellsborg’s Foundation.

Acknowledgements
The authors thank the staff at the Department of Cardiology, Gentofte Hospital, Denmark, for providing them with their database on patients with cardiovascular disease appointed to rehabilitation. They are thankful to the staff of the Metabolic Ward for their contributions concerning practical issues: Helle-Marina Oxfeldt, Tine Skogen-Lassen, Ulla Kjærulf-Hansen, Tonna Løve Hansen, Hanne Dørthe Mogensen, and Marianne Sørensen and Rikke Mirsbach Henkel.

References


**Received in final form 28 July 2014**

**Accepted 19 August 2014**